Latest respiratory distress Stories
WARRINGTON, Pa., April 15, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the U.S. Food and Drug Administration (FDA) has requested clarification and provided recommendations regarding the recently-updated product specifications for SURFAXIN(®). Discovery Labs plans to provide a response to the FDA within two months. FDA procedure provides up...
WARRINGTON, Pa., March 29, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to SURFAXIN(®) (lucinactant) Intratracheal Suspension. SURFAXIN, currently the only FDA approved synthetic alternative to animal-derived surfactants in the U.S., was highlighted in the December issue of the Journal of...
WARRINGTON, Pa., Feb. 13, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that it has entered into a secured loan facility with Deerfield Management Company, L.P. (Deerfield) for up to $30.0 million in financing. Deerfield is a leading healthcare investment firm with more than $3.5 billion of assets currently under management. "We are...
WARRINGTON, Pa., Sept. 6, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the publication of SURFAXIN(® )(lucinactant) preclinical data in Pediatric Research. Using a well-established preterm lamb model of respiratory distress syndrome (RDS), study investigators concluded that early intervention with SURFAXIN may mitigate progression of pulmonary...
Receives $2.3 million from Bill & Melinda Gates Foundation to complete development of affordable respiratory support device SEATTLE, Aug. 16, 2011 /PRNewswire-USNewswire/ -- Seattle Children's Research Institute today announced the receipt of a two-year, $2.3 million grant from the Bill & Melinda Gates Foundation to complete prototype development of its new respiratory support device, called Seattle Children's Positive Airway Pressure (Sea-PAP.) Sea-PAP, designed to be an...
